- Home
- CSR vs ARDX Comparison
CSR vs ARDX Comparison
Compare CSR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- ARDX
- Stock Information
- Founded
- CSR 1970
- ARDX 2007
- Country
- CSR United States
- ARDX United States
- Employees
- CSR N/A
- ARDX N/A
- Industry
- CSR Real Estate Investment Trusts
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- ARDX Health Care
- Exchange
- CSR Nasdaq
- ARDX Nasdaq
- Market Cap
- CSR 997.0M
- ARDX 882.9M
- IPO Year
- CSR N/A
- ARDX 2014
- Fundamental
- Price
- CSR $60.52
- ARDX $6.52
- Analyst Decision
- CSR Buy
- ARDX Strong Buy
- Analyst Count
- CSR 7
- ARDX 9
- Target Price
- CSR $70.00
- ARDX $10.50
- AVG Volume (30 Days)
- CSR 98.4K
- ARDX 3.5M
- Earning Date
- CSR 10-27-2025
- ARDX 10-30-2025
- Dividend Yield
- CSR 5.16%
- ARDX N/A
- EPS Growth
- CSR N/A
- ARDX N/A
- EPS
- CSR N/A
- ARDX N/A
- Revenue
- CSR $267,076,000.00
- ARDX $386,146,000.00
- Revenue This Year
- CSR $5.37
- ARDX $16.83
- Revenue Next Year
- CSR $3.01
- ARDX $28.55
- P/E Ratio
- CSR N/A
- ARDX N/A
- Revenue Growth
- CSR 3.44
- ARDX 83.88
- 52 Week Low
- CSR $52.76
- ARDX $3.21
- 52 Week High
- CSR $76.16
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- CSR 65.77
- ARDX 79.80
- Support Level
- CSR $57.07
- ARDX $6.38
- Resistance Level
- CSR $59.68
- ARDX $6.65
- Average True Range (ATR)
- CSR 1.17
- ARDX 0.22
- MACD
- CSR 0.51
- ARDX 0.00
- Stochastic Oscillator
- CSR 93.18
- ARDX 85.53
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.